^
    1d
    A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=132, Not yet recruiting, Akeso
    New P2 trial
    |
    Idafang (ivonescimab)
    5d
    BIO-PROSA: Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Regina Elena Cancer Institute | Trial completion date: Jun 2025 --> Jun 2027
    Trial completion date • Real-world evidence
    |
    Trodelvy (sacituzumab govitecan-hziy)
    5d
    STARTER: Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • ER negative
    |
    capecitabine • Jiataile (sacituzumab tirumotecan)
    6d
    Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan-An International CEBCC Study from Poland, the Czech Republic and Slovakia. (PubMed, Oncol Res)
    In multivariable analysis, Eastern Cooperative Oncology Group (ECOG) performance status was the only independent predictor of poorer survival (hazard ratio 1.97, 95% CI 1.42-2.74, p < 0.01), while gBRCA1/2 status showed no independent association. In this large retrospective cohort of mTNBC patients treated with SG, the presence of gBRCA1/2 was not associated with statistically significant differences in PFS or OS.
    Clinical data • Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    Trodelvy (sacituzumab govitecan-hziy)
    7d
    Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases (clinicaltrials.gov)
    P2, N=24, Recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative • HER-2 negative + HR negative
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
    9d
    Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jiataile (sacituzumab tirumotecan)
    9d
    VELOCITY-Lung: Study of Novel Treatment Combinations in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=192, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)
    12d
    Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. (PubMed, Lancet)
    Among patients with PD-L1-positive advanced NSCLC without targetable genomic alterations, first-line treatment with sac-TMT plus pembrolizumab significantly prolonged progression-free survival compared with pembrolizumab alone. Therefore, sac-TMT plus pembrolizumab has the potential to redefine first-line treatment for patients with PD-L1-positive advanced NSCLC without targetable genomic alterations.
    P3 data • P3 data: top line • Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Jiataile (sacituzumab tirumotecan)
    14d
    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)
    P3, N=686, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • Jiataile (sacituzumab tirumotecan) • Tivdak (tisotumab vedotin-tftv)
    14d
    Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions. (PubMed, Future Oncol)
    SG's success in breast cancer and broad expression in epithelial tumors has sparked interest in its potential applicability to CRC. This review provides an overview of SG's mechanism of action and current clinical applications, discussing its therapeutic potential in the context of CRC.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Trodelvy (sacituzumab govitecan-hziy)
    16d
    Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer. (PubMed, Front Public Health)
    To improve patient access, substantial price reductions or inclusion in the National Reimbursement Drug List are necessary. These findings may inform both clinical decisions and health resource allocation.
    Journal • HEOR • Cost-effectiveness
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Jiataile (sacituzumab tirumotecan)
    16d
    TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer. (PubMed, Ther Adv Med Oncol)
    TROPION-Lung14 will assess 1L osimertinib + Dato-DXd versus osimertinib alone in patients with EGFR-mutated LA/M NSCLC, potentially providing a new treatment option. ClinicalTrials.gov identifier: NCT06350097 (Registration Date: April 5, 2024).
    P3 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Datroway (datopotamab deruxtecan-dlnk)